Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Virtual PrEP delivery using mHealth and TAF/FTC
NCT05159531Phase 4Terminated
- Sponsor
- Unity Health Toronto
- Start
- May 2023
- Primary completion
- Jun 2023
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by Unity Health Toronto. Primary endpoint: Participant stated preference for model of care at 72 weeks. Started May 2023; status: terminated.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05159531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05159531.